/ 2 items

#ARMP↓

ARMP/ 07/20/2026 · 11:35 AM

Armata Clears Key FDA Milestone, Prepares AP-SA02 Phase 3 Trial for 2026

Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.

Methicillin-resistant Staphylococcus aureus (MRSA)

ARMP/ 10/22/2025 · 11:52 AM

Armata Pharmaceuticals Shows Promising Results for AP-SA02 in Severe Staph Infection

Armata's AP-SA02 bacteriophage cocktail showed high cure rates and zero relapse in a Phase 2 trial for complicated Staphylococcus aureus bacteremia (SAB), signaling a potential new standard of care.